UPC Analytics
ENDE
Overview · Filed: —

UPC_APP_9038/2025

METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Procedural & sub-applicationsInterventionMilan CDApplication Rop313—
OverviewDecisionsCitationsDocumentsTimeline
Parties

Claimants

  • Zentiva, k.s.
  • ZENTIVA PORTUGAL, LDA
Reps: Marc Lauzeral

Respondents

  • Accord Healthcare B.V.
  • Accord Healthcare S.L.U.
  • ACCORD HEALTHCARE LIMITED,
  • Novartis AG
Reps: Gregory Bacon (Bristows (Ireland) LLP); Rutger Kleemans (Freshfields); Daniela Ampollin (Trevisan & Cuonzo); Allard van Duijn (Freshfields)
Judges
  • —
Patents
  • EP 2 501 384
CPC codes: A61P11/06, A61P37/06, A61P43/00, A61P17/00, A61P9/12, A61K31/506, A61P17/06, A61P19/02, A61P25/28, A61P35/00, A61K31/505, C07D239/69…

Sector: Organic Chemistry

Outcome
Dismissed
Filed: —
First decided: Mar 21, 2025
Language: —

The Milan Central Division dismissed Zentiva K.S. and Zentiva Portugal's application to intervene under Rule 313 RoP in infringement proceedings between Accord Healthcare and Novartis concerning EP 2 501 384. The court held that parallelism between cases or the potential impact of one judgment on another does not establish the legal interest required for intervention, and that the intervening party's requested remedies must be non-contradictory to those of the supported party.